This report was first published by Endpoints News. To see the original version, click here
A new biotech has raised $100 million to build a mix of assets from inside and outside China, while developing its own drug candidates.
The Shanghai-based startup, called OTR Therapeutics, is a new twist on Western investors that build new companies around Chinese drug candidates. The company wants to take advantage of the rapid development and clinical work available in the region, but with assets that can come from anywhere.
您已阅读17%（519字），剩余83%（2520字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。